The global Neuropeptide Y Receptor Market Comprehensive Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Product (Food Grade, Pharmaceutical Grade), By End-User (Medicine, Food Additives, Others)
The Neuropeptide Y Receptor Market focuses on the research and development of therapies targeting neuropeptide Y receptors, which play a role in regulating appetite, stress response, and circadian rhythms. The market is driven by increasing prevalence of metabolic and neurological disorders, rising demand for innovative therapeutic solutions, and growing investment in pharmaceutical research. Additionally, advancements in receptor targeting technologies and the expansion of clinical trials support market growth.
The market report analyses the leading companies in the industry including Eli Lilly & Co, Genentech Inc, Gila Therapeutics Inc, Gilead Sciences Inc, Mannkind Corp, Merck & Co. Inc, Novartis AG, Novo Nordisk A/S, Pfizer Inc, XL-protein GmbH, and Others.
The most prominent trend in the Neuropeptide Y Receptor Market is the focus on targeted therapeutics. Researchers are increasingly exploring neuropeptide Y receptors as potential targets for treating various neurological and psychiatric disorders, driven by the need for more effective and specific treatments.
A key driver in the Neuropeptide Y Receptor Market is the increasing prevalence of mental health disorders. As the incidence of conditions like anxiety, depression, and obesity rises, there is a growing demand for novel therapeutics targeting neuropeptide Y receptors, which play a significant role in these conditions.
One significant opportunity in the Neuropeptide Y Receptor Market lies in the development of new drug classes. Companies can innovate by creating novel compounds that modulate neuropeptide Y receptors, offering new treatment options for patients and potentially capturing a significant market share.
In the Neuropeptide Y Receptor Market, the Pharmaceutical Grade segment is the largest. This segment's dominance is due to the significant investments in research and development for therapeutic applications. Neuropeptide Y receptors are crucial in studying and developing treatments for various neurological and metabolic disorders, which drives demand for high-purity pharmaceutical-grade products. The extensive use of these receptors in clinical trials and drug development makes pharmaceutical-grade products the most significant segment in the market.
The Medicine end-user segment is poised to grow the fastest in the Neuropeptide Y Receptor Market over the next five years. This growth is driven by increasing research into neurological disorders and the potential of neuropeptide Y receptors in therapeutic applications. Advances in drug development and the rising prevalence of conditions such as obesity, anxiety, and depression are leading to higher demand for neuropeptide Y receptor products in medical research and pharmaceutical applications. The expansion of clinical trials and new drug discoveries are key factors contributing to this rapid growth.
By Product
Food Grade
Pharmaceutical Grade
By End-User
Medicine
Food Additives
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Eli Lilly & Co
Genentech Inc
Gila Therapeutics Inc
Gilead Sciences Inc
Mannkind Corp
Merck & Co. Inc
Novartis AG
Novo Nordisk A/S
Pfizer Inc
XL-protein GmbH
*- List Not Exhaustive
Chapter 1. TABLE OF CONTENTS
Chapter 2. Introduction to Neuropeptide Y Receptor Market
2.1. Market Overview
2.2. Key Statistics and Report Highlights
2.3. Scope of the Comprehensive Study
2.3.1. Market Definition
2.3.2 Countries and Regions Covered
2.3.3 Research Objective
2.3.4 Units, Currency, and Conversions
2.3.5 Industry Value Chain
2.4. Key Market Segments
2.5. Key Companies
2.6. Study Period
Chapter 3. Strategic Analysis Review
3.1. Neuropeptide Y Receptor Pricing Analysis and Forecast
3.2. Porter’s Five Forces
3.3. Market Ecosystem
3.4. SWOT Analysis
3.5. Regulatory Scenario
3.3. Effects of Inflation, Russia-Ukraine War, moderating economic growth, and other macroeconomic factors
Chapter 4. Competitive Landscape
4.1. Market Share Analysis
4.1.1. Global Neuropeptide Y Receptor Market Share by Company, 2023
4.1.2. Product Offerings of Leading Neuropeptide Y Receptor Companies
4.2. Market Entropy
4.2.1. New Product Launches in the Industry
4.2.2. Mergers, Acquisitions, Joint ventures, and Partnerships
4.3. Key Strategies and Best Practices
Chapter 5. Global Market Projections: Best, Reference, and Low Case Scenarios
5.1. Growth Analysis- Case Scenario Definitions
5.2. Low Growth Case Scenario Forecasts
5.3. Reference Growth Case Scenario Forecasts
5.4. High Growth Case Scenario Forecasts
Chapter 6. Market Dynamics
6.1. Neuropeptide Y Receptor Market Drivers
6.2. Neuropeptide Y Receptor Market Challenges
6.6. Neuropeptide Y Receptor Market Opportunities
6.4. Neuropeptide Y Receptor Market Trends
Chapter 7. Global Neuropeptide Y Receptor Market Outlook Trends
7.1. Global Neuropeptide Y Receptor Revenue (USD Million) and CAGR (%) by Type (2021-2032)
7.2. Global Neuropeptide Y Receptor Revenue (USD Million) and CAGR (%) by Application (2021-2032)
7.3. Global Neuropeptide Y Receptor Revenue (USD Million) and CAGR (%) by Product (2021-2032)
By Product
Food Grade
Pharmaceutical Grade
By End-User
Medicine
Food Additives
Others
Chapter 8. Global Neuropeptide Y Receptor Regional Analysis and Outlook
8.1. Global Neuropeptide Y Receptor Revenue (USD Million) By Regions (2021- 2032)
8.2. North America Neuropeptide Y Receptor Revenue (USD Million) by Country (2021-2032)
8.2.1. United States Neuropeptide Y Receptor Regional Analysis and Outlook
8.2.2. Canada Neuropeptide Y Receptor Regional Analysis and Outlook
8.2.3. Mexico Neuropeptide Y Receptor Regional Analysis and Outlook
8.3. Europe Neuropeptide Y Receptor Revenue (USD Million), by Country (2021-2032)
8.3.1. Germany Neuropeptide Y Receptor Regional Analysis and Outlook
8.3.2. France Neuropeptide Y Receptor Regional Analysis and Outlook
8.3.3. United Kingdom Neuropeptide Y Receptor Regional Analysis and Outlook
8.3.4. Spain Neuropeptide Y Receptor Regional Analysis and Outlook
8.3.5. Italy Neuropeptide Y Receptor Regional Analysis and Outlook
8.3.6. Russia Neuropeptide Y Receptor Regional Analysis and Outlook
8.3.7. Rest of Europe Neuropeptide Y Receptor Regional Analysis and Outlook
8.4. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) by Country (2021-2032)
8.4.1. China Neuropeptide Y Receptor Regional Analysis and Outlook
8.4.2. Japan Neuropeptide Y Receptor Regional Analysis and Outlook
8.4.3. India Neuropeptide Y Receptor Regional Analysis and Outlook
8.4.4. South Korea Neuropeptide Y Receptor Regional Analysis and Outlook
8.4.5. Australia Neuropeptide Y Receptor Regional Analysis and Outlook
8.4.6. South East Asia Neuropeptide Y Receptor Regional Analysis and Outlook
8.4.7. Rest of Asia Pacific Neuropeptide Y Receptor Regional Analysis and Outlook
8.5. South America Neuropeptide Y Receptor Revenue (USD Million), by Country (2021-2032)
8.5.1. Brazil Neuropeptide Y Receptor Regional Analysis and Outlook
8.5.2. Argentina Neuropeptide Y Receptor Regional Analysis and Outlook
8.5.3. Rest of South America Neuropeptide Y Receptor Regional Analysis and Outlook
8.6. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) by Country (2021-2032)
8.6.1. Middle East Neuropeptide Y Receptor Regional Analysis and Outlook
8.6.2. Africa Neuropeptide Y Receptor Regional Analysis and Outlook
Chapter 9. North America Neuropeptide Y Receptor Analysis and Outlook
9.1. North America Neuropeptide Y Receptor Revenue (USD Million) by Segments (2021-2032)
9.1.1. North America Neuropeptide Y Receptor Revenue (USD Million) by Type (2021-2032)
9.1.2. North America Neuropeptide Y Receptor Revenue (USD Million) by Application (2021-2032)
9.1.3. North America Neuropeptide Y Receptor Revenue (USD Million) by Product (2021-2032)
By Product
Food Grade
Pharmaceutical Grade
By End-User
Medicine
Food Additives
Others
Chapter 10. Europe Neuropeptide Y Receptor Analysis and Outlook
10.1. Europe Neuropeptide Y Receptor Revenue (USD Million), by Segments (USD Million) (2021-2032)
10.1.1. Europe Neuropeptide Y Receptor Revenue (USD Million) by Type (2021-2032)
10.1.2. Europe Neuropeptide Y Receptor Revenue (USD Million) by Application (2021-2032)
10.1.3. Europe Neuropeptide Y Receptor Revenue (USD Million) by Product (2021-2032)
By Product
Food Grade
Pharmaceutical Grade
By End-User
Medicine
Food Additives
Others
Chapter 11. Asia Pacific Neuropeptide Y Receptor Analysis and Outlook
11.1. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million), and Revenue (USD Million) by Segments (2021-2032)
11.1.1. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) by Type (2021-2032)
11.1.2. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) by Application (2021-2032)
11.1.3. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) by Product (2021-2032)
By Product
Food Grade
Pharmaceutical Grade
By End-User
Medicine
Food Additives
Others
Chapter 12. South America Neuropeptide Y Receptor Analysis and Outlook
12.1. South America Neuropeptide Y Receptor Revenue (USD Million), by Segments (2021-2032)
12.1.1. South America Neuropeptide Y Receptor Revenue (USD Million) by Type (2021-2032)
12.1.2. South America Neuropeptide Y Receptor Revenue (USD Million) by Application (2021-2032)
12.1.3. South America Neuropeptide Y Receptor Revenue (USD Million) by Product (2021-2032)
By Product
Food Grade
Pharmaceutical Grade
By End-User
Medicine
Food Additives
Others
Chapter 13. Middle East and Africa Neuropeptide Y Receptor Analysis and Outlook
13.1. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million), by Segments (2021-2032)
13.1.1. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) by Type (2021-2032)
13.1.2. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) by Application (2021-2032)
13.1.3. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) by Product (2021-2032)
By Product
Food Grade
Pharmaceutical Grade
By End-User
Medicine
Food Additives
Others
Chapter 14. Neuropeptide Y Receptor Company Profiles
14.1 Business Overview
14.2 Product Profiles
14.3 SWOT Profiles
14.5 Recent Developments
14.6 Financial Profile
List of Companies
Eli Lilly & Co
Genentech Inc
Gila Therapeutics Inc
Gilead Sciences Inc
Mannkind Corp
Merck & Co. Inc
Novartis AG
Novo Nordisk A/S
Pfizer Inc
XL-protein GmbH
15. Methodology and Data Sources
15.1 Customization Offerings
15.2 Subscription Services
15.3 Related Reports
15.4 Publisher Expertise
LIST OF TABLES
Table 1 Market Segmentation Analysis
Table 2 Global Neuropeptide Y Receptor Market Share of Leading Companies, 2023
Table 3 Product Offerings of Leading Companies
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Neuropeptide Y Receptor Revenue (USD Million) And CAGR (%) By Type (2021-2032)
Table 8 Global Neuropeptide Y Receptor Revenue (USD Million) And CAGR (%) By Application (2021-2032)
Table 9 Global Neuropeptide Y Receptor Revenue (USD Million) And CAGR (%) By Product (2021-2032)
Table 10 Global Neuropeptide Y Receptor Market Revenue (USD Million) By Regions (2021-2032)
Table 11 Global Neuropeptide Y Receptor Market Share (%) By Regions (2021-2032)
Table 12 North America Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Table 13 Europe Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Table 14 Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Table 15 South America Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Table 16 Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) By Region (2021-2032)
Table 17 North America Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Table 18 North America Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Table 19 North America Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
Table 20 Europe Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Table 21 Europe Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Table 22 Europe Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
Table 23 Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Table 24 Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Table 25 Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
Table 26 South America Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Table 27 South America Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Table 28 South America Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
Table 29 Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Table 30 Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Table 31 Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
LIST OF FIGURES
Figure 1. Market Scope
Figure 2. Pricing Forecasts Per Unit, 2023- 2032
Figure 3. Porter’s Five Forces
Figure 4. Global Neuropeptide Y Receptor Market Revenue (USD Million) By Regions (2021-2032)
Figure 5. Global Neuropeptide Y Receptor Market Share (%) By Regions (2023)
Figure 6. North America Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 7. United States Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 8. Canada Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 9. Mexico Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 10. Europe Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 11. Germany Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 12. France Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 13. United Kingdom Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 14. Spain Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 15. Italy Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 16. Russia Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 17. Rest of Europe Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 11. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 12. China Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 13. Japan Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 14. India Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 15. South Korea Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 16. Australia Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 17. South East Asia Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 18. South America Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 19. Brazil Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 20. Argentina Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 21. Rest of Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Country (2021-2032)
Figure 22. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) By Region (2021-2032)
Figure 23. Saudi Arabia Neuropeptide Y Receptor Revenue (USD Million) By Region (2021-2032)
Figure 24. The UAE Neuropeptide Y Receptor Revenue (USD Million) By Region (2021-2032)
Figure 25. Rest of Middle East Neuropeptide Y Receptor Revenue (USD Million) By Region (2021-2032)
Figure 26. South Africa Neuropeptide Y Receptor Revenue (USD Million) By Region (2021-2032)
Figure 27. Africa Neuropeptide Y Receptor Revenue (USD Million) By Region (2021-2032)
Figure 28. North America Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Figure 29. North America Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Figure 30. North America Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
Figure 31. Europe Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Figure 32. Europe Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Figure 33. Europe Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
Figure 34. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Figure 35. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Figure 36. Asia Pacific Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
Figure 37. South America Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Figure 38. South America Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Figure 39. South America Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
Figure 40. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) By Type (2021-2032)
Figure 41. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) By Application (2021-2032)
Figure 42. Middle East and Africa Neuropeptide Y Receptor Revenue (USD Million) By Product (2021-2032)
By Product
Food Grade
Pharmaceutical Grade
By End-User
Medicine
Food Additives
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Global Neuropeptide Y Receptor Market Size is valued at $XX Million in 2024 and is forecast to register a growth rate (CAGR) of 6.8% to reach $XX Million by 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Eli Lilly & Co, Genentech Inc, Gila Therapeutics Inc, Gilead Sciences Inc, Mannkind Corp, Merck & Co. Inc, Novartis AG, Novo Nordisk A/S, Pfizer Inc, XL-protein GmbH
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2032; Currency: Revenue (USD); Volume